CRDL Stock Quote
| Symbol: | CRDL |
|---|---|
| Quote: | 1.06 |
| Change: | +0.00 |
| Change %: | +0.01% |
| High: | 1.08 |
| Low: | 1.04 |
| Open: | 1.04 |
|---|---|
| Volume: | 123,132 |
| 52 Week: | 0.77-3.12 |
| P/E Ratio: | -3.12 |
| EPS: | -0.34 |
| Market Cap: | 87.60 M |
Company Report
Cardiol Therapeutics Inc. is a clinical-stage life sciences company based in Oakville, Canada, dedicated to advancing therapies for cardiovascular disease (CVD) through innovative anti-fibrotic and anti-inflammatory treatments. At the forefront of its research is CardiolRx, the company's leading product currently undergoing Phase II/III multi-national trials. These studies are pivotal in assessing CardiolRx's efficacy and safety as a cardioprotective therapy aimed at reducing cardiovascular and respiratory events in hospitalized COVID-19 patients, as well as its potential in treating acute myocarditis.
In addition to its ongoing clinical trials, Cardiol Therapeutics is actively developing a subcutaneous formulation of CardiolRx. This formulation is specifically tailored to target fibrosis and inflammation in the heart, conditions intricately linked to the progression and development of heart failure. By focusing on these critical areas of cardiovascular health, the company aims to adress significant unmet medical needs and improve patient outcomes.
Founded in 2017, Cardiol Therapeutics has quickly positioned itself as a leader in the field of cardiovascular therapeutics. The company's headquarters in Oakville serve as a hub for its research and development efforts, bolstered by a commitment to rigorous scientific inquiry and strategic partnerships aimed at advancing novel treatments that hold promise for patients worldwide.
CRDL EPS Chart
CRDL Revenue Chart
CRDL Profile
| Exchange: | NASDAQ |
|---|---|
| Beta: | 0.66388375 |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Employees: | 18 |
| IPO Date: | Jan 15, 2019 |
CRDL News
Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industry experience Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therap... 23 days ago |
Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors. 1 months ago |
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago. Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application. 1 months ago |
Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patientswith acute myocarditis, with topline... 1 months ago |
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the TD Cowen 45th Annual... 2 months ago |
Analyst Ratings